FXIII structure and function
Li B, Bechtler C, Jenny L, Ricklin D, Schroeder V. Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners. Res Pract Thromb Haemost 2022; 6: e12766.
Schroeder V. Intermolecular interactions that stabilize multimeric FXIII. In: Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress. Res Pract Thromb Haemost 2021; 5: e12532. [Invited graphical abstract for my State-of-the-Art Presentation at ISTH congress 2021]
Li B, Kohler HP, Schroeder V. Identification of amino acid residues that are crucial for FXIII-A intersubunit interactions and stability. Blood 2020; 135: 145-152.
Orosz ZZ, Bardos H, Shemirani AH, Beke Debreceni I, Lassila R, Riikonen AS, Kremer Hovinga JA, Seiler TG, van Dorland HA, Schroeder V, Boda Z, Nemes L, Früh Eppstein B, Nagy B, Facskó A, Kappelmayer J, Muszbek L. Cellular factor XIII, a transglutaminase in human corneal keratocytes. Int J Mol Sci 2019; 20: 5963.
Schroeder V, Kohler HP. Factor XIII, structure and function. Semin Thromb Hemost 2016; 42: 422-428. [Review article]
Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost 2013; 11: 234-244. [Review article]
Schroeder V, Kohler HP. Faktor XIII. In: Pötzsch B, Madlener K (eds.). Hämostaseologie. 2nd edn. Springer Verlag; Berlin, Heidelberg. 2010. [Book chapter]
Schroeder V, Kohler HP. Thrombelastographic studies on factor XIII. Thromb Haemost 2010; 104: 1277-1279.
Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104: 467-474.
Schröder V, Kohler HP. Effect of factor XIII Val34Leu on α2-antiplasmin incorporation into fibrin. Thromb Haemost 2000; 84: 1128-1130.
FXIII activation peptide
Handrkova H, Schroeder V, Kohler HP. The activation peptide of coagulation factor XIII is vital for its expression and stability. J Thromb Haemost 2015; 13: 1449-1458.
Schroeder V, Handrkova H, Dodt J, Kohler HP. Free factor XIII activation peptide affects factor XIII function. Br J Haematol 2015; 168: 757-759.
Schroeder V, Ortner E, Mono ML, Galimanis A, Meier N, Findling O, Fischer U, Brekenfeld C, Arnold M, Mattle HP, Kohler HP. Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study. Thromb Res 2010; 126: e122-127.
Ortner E, Schroeder V, Walser R, Zerbe O, Kohler HP. Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood 2010; 115: 5089-5096.
Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost 2007; 97: 890-898.
Schroeder V, Kohler HP. Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype. Blood 2003; 101: 371-2.
FXIII deficiency
Schroeder V. Laboratory assessment of coagulation factor XIII. Hämostaseologie 2020; 40: 467-471. [Invited review]
Li B, Billur R, Maurer MC, Kohler HP, Raddatz Müller P, Alberio L, Schroeder V. Proline 36 of the factor XIII activation peptide plays a crucial role in substrate recognition and zymogen activation. Thromb Haemost 2018; 118: 2037-2045.
Li B, Borhany M, Abid M, Kohler HP, Schroeder V. Identification of a novel nonsense mutation leading to congenital factor XIII deficiency. Thromb Res 2018; 165: 83-85.
Handrkova H, Borhany M, Schroeder V, Fatima N, Hussain A, Shamsi T, Kohler HP. Identification of two novel missense mutations causing severe factor XIII deficiency. Haemophilia 2015; 21: e253-256.
Borhany M, Handrkova H, Cairo A, Schroeder V, Fatima N, Naz A, Amanat S, Shamsi T, Peyvandi F, Kohler HP. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia 2014; 20: 568-574.
Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39: 632-641. [Review article]
Boehlen F, Casini A, Chizzolini C, Mansouri B, Kohler HP, Schroeder V, Reber G, de Moerloose P. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109: 479-487.
Pasquier E, De Saint Martin L, Kohler HP, Schroeder V. Factor XIII plasma levels in women with unexplained recurrent pregnancy loss. J Thromb Haemost 2012; 10: 723-725.
Castaman G, Giacomelli SH, Schroeder V, Sanna S, Valdrè L, Morfini M, Banov L, Kohler HP, Rodeghiero F. Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency. Haemophilia 2012; 18: e6-8.
Ivaskevicius V, Biswas A, Loreth R, Schroeder V, Ohlenforst S, Rott H, Krause M, Kohler HP, Scharrer I, Oldenburg J. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: Results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010; 16: 675-682.
Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H, Halimeh S, Petrides PE, Lenk H, Krause M, Miterski B, Harbrecht U, Oldenburg J. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95: 956-962.
Castaman G, Giacomelli SH, Ivaskevicius V, Schroeder V, Kohler HP, Dragani A, Biasioli C, Oldenburg J, Madeo D, Rodeghiero F. Molecular characterization of five Italian families with inherited severe factor XIII deficiency. Haemophilia 2008; 14: 96-102.
Ivaskevicius V, Windyga J, Baran B, Schroeder V, Junen J, Bykowska K, Seifried E, Kohler HP, Oldenburg J. Phenotype-genotype correlation in eight Polish patients with inherited factor XIII deficiency: identification of three novel mutations. Haemophilia 2007; 13: 649-657.
Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RAS, Seifried E, Oldenburg J, and Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97: 914-921.
Schroeder V, Meili E, Cung T, Schmutz P, Kohler HP. Characteristion of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thromb Haemost 2006; 95: 77-84.
Schroeder V, Durrer D, Meili E, Schubiger G, Kohler HP. Congenital factor XIII deficiency in Switzerland: From the worldwide first case in 1960 to its molecular characterisation in 2005. Swiss Med Wkly 2007; 137: 272-278. [Review article]
Wilmer M, Schröder V, Kohler HP. Methoden zur Bestimmung des Faktors XIII/XIIIa. Hämostaseologie 2002; 22: 18-28. [Review article]
FXIII in vascular diseases
Li B, Heldner MR, Arnold M, Coutinho JM, Zuurbier SM, Meijers JCM, Kohler HP, Schroeder V. Coagulation factor XIII in cerebral venous thrombosis. TH Open 2019; 3: e227-e229.
Kool RO, Kohler HP, Coutinho JM, Levi M, Coppens M, Meijers JCM, Schroeder V. Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. Thromb Res 2017; 159: 96-99.
Zeerleder S, Schroeder V, Lämmle B, Wuillemin WA, Hack CE, Kohler HP. Factor XIII in severe sepsis and septic shock. Thromb Res 2007; 119: 311-318.
Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 2003; 90: 434-438.
Chatterjee T, Schroeder V, Windecker S, Meier B, Kohler HP. Venous and intracoronary factor XIII A-subunit antigen and activity levels are not associated with extent of coronary artery disease. J Thromb Haemost 2003; 1: 861-863.
Kohler HP, Schröder V. Die Rolle von Faktor XIII bei kardio- und zerebrovaskulären Erkrankungen. Hämostaseologie 2002; 22: 39-44. [Review article]
Complement system and coagulation
Golomingi M, Kohler J, Lamers C, Pouw RB, Ricklin D, Dobó J, Gál P, Pál G, Kiss B, Dopler A, Schmidt CQ, Hardy ET, Lam W, Schroeder V. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. Front Immunol 2023; 14: 1226832.
Golomingi M, Kohler J, Jenny L, Hardy ET, Dobó J, Gál P, Pál G, Kiss B, Lam WA, Schroeder V. Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model. Front Immunol 2022; 13: 948190.
Ajjan RA, Schroeder V. Role of complement in diabetes. Mol Immunol 2019; 114: 270-277. [Invited review for the special issue for the European Meeting on Complement in Human Diseases EMCHD 2019]
Jenny L, Noser D, Larsen JB, Dobo J, Gal P, Pal G, Schroeder V. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Mol Immunol 2019; 114: 1-9.
Jenny L, Dobo J, Gal P, Pal G, Lam WA, Schroeder V. MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model. PLoS ONE 2018; 13: e0191292.
Jenny L, Dobo J, Gal P, Schroeder V. MASP-1 induced clotting – the first model of prothrombin activation by MASP-1. PLoS ONE 2015; 10: e0144633.
Jenny L, Dobo J, Gal P, Schroeder V. MASP-1 of the complement system promotes clotting via prothrombin activation. Mol Immunol 2015; 65: 398-405.
Jenny L, Ajjan R, King R, Thiel S, Schroeder V. Plasma levels of MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control. Clin Exp Immunol 2015; 180: 227-232.
Dobo J, Schroeder V, Jenny L, Cervenak L, Zavodszky P, Gal P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol 2014; 61: 69-78. [Invited review for the special issue for the International Complement Workshop ICW 2014]
Hess K, Alzahrani SH, Price JF, Strachan MW, Oxley N, King R, Gamlen T, Schroeder V, Baxter PD, Ajjan RA. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. Diabetologia 2014; 57: 1737-1741.
Frauenknecht V, Thiel S, Storm L, Meier N, Arnold M, Schmid JP, Saner H, Schroeder V. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin Exp Immunol 2013; 173: 112-120.
Richardson VR, Schroeder V, Grant PJ, Standeven KF, Carter AM. Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. Br J Haematol 2013; 160: 116-119.
Frauenknecht V, Schroeder V. Das Komplementsystem – ein phylogenetisch altes System als neuer Mitspieler bei der Entstehung der Atherosklerose. Hämostaseologie 2012; 32: 276-285. [Review article]
Hess K, Ajjan R, Phoenix F, Dobo J, Gal P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One 2012; 7: e35690.
Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, Shore A, Hess K, Ajjan R, Pease RJ, Keen JN, Standeven KF, Carter AM. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9: 216-225.
Hess K, Alzahrani S, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MWJ, Price JF, Smith KA, Grant PJ, Ajjan RA. A novel mechanism for hypofibrinolysis in diabetes: The role of Complement C3. Diabetologia 2012; 55: 1103-1113.
Schroeder V, Carter AM, Dunne J, Mansfield MW, Grant PJ. Proinflammatory and hypofibrinolytic phenotype in healthy first-degree relatives of patients with type 2 diabetes. J Thromb Haemost 2010; 8: 2080-2082.
Various publications
Mutch NJ, Walters S, Gardiner EE, McCarty OJT, De Meyer SF, Schroeder V, Meijers JCM. Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. J Thromb Haemost 2022; 20: 1496-1506.
Raut S, Katona E, Riches-Duit A, Coxon C, Muszbek L, Schroeder V, Rigsby P. An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. J Thromb Haemost 2022; 20: 525-531.
Sánchez van Kammen M, Heldner MR, Brodard J, Scutelnic A, Silvis S, Schroeder V, Kremer Hovinga JA, Middeldorp S, Levi M, Hiltunen S, Lindgren E, Mansour M, Arauz A, Barboza MA, Zuurbier SM, Aguiar de Sousa D, Ferro JM, Fischer U, Field TS, Jood K, Tatlisumak T, Putaala J, Arnold M, Coutinho JM. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA 2021; 326: 332-338.
Heldner MR, Zuurbier SM, Li B, Von Martial R, Meijers JCM, Zimmermann R, Volbers B, Jung S, El-Koussy M, Fischer U, Kohler HP, Schroeder V, Coutinho JM, Arnold M. Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. Neurology 2020; 95: e898-e909.
Jenny L, Melmer A, Laimer M, Trybus Hardy E, Lam WA, Schroeder V. Diabetes affects endothelial cell function and alters fibrin clot formation in a microvascular flow model: a pilot study. Diab Vas Dis Res 2020; 17: 1479164120903044.
Engelberger RP, Schroeder V, Nagler M, Prince R, Périard D, Hayoz D, Kucher N. Enhanced thrombolysis by ultrasound-assisted catheter-directed thrombolysis and microbubbles in an in vitro model of iliofemoral deep vein thrombosis. Thromb Haemost 2019; 119: 1094-1101.
Polkinghorne VR, Standeven KF, Schroeder V, Carter AM. Role of proteomic technologies in understanding risk of arterial thrombosis. Expert Rev Proteomics 2009; 6: 539-550. [Review article]
Schroeder V, Borner U, Gutknecht S, Schmid JP, Saner H, Kohler HP. Relation of depression to various markers of coagulation and fibrinolysis in patients with and without coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007; 14: 782-787.
Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays. Thromb Haemost 2006; 96: 236-237.
Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-212.
Schmid JP, Schroeder V. Nicorandil – Review of pharmacological properties and clinical applications. Heart Drug 2005; 5: 220-229. [Review article]
Oppliger Leibundgut E, Brunold C, Marti D, Horn MP, Seiler C, Schroeder V, Schmid JP, Tobler A, Zwicky C. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction. Haematologica 2005; 90: 875-880.
Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J Thromb Haemost 2003; 1: 492-493.
Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-1025.
Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 2002; 74: 1147-1152.
